Form 4: Jazz Pharmaceuticals Executive Sells Shares

Jazz Pharmaceuticals executive Samantha Pearce reported a disposition of ordinary shares, primarily to cover tax obligations.

Summary

• Samantha Pearce, EVP, Chief Commercial Officer of Jazz Pharmaceuticals plc, reported a transaction involving ordinary shares on June 30, 2026.
• A total of 2,527 ordinary shares were disposed of, with the transaction code 'F' indicating shares withheld to satisfy tax obligations from the vesting of restricted stock units.
• The reported price for these shares was $237.72.
• Following this transaction, Ms. Pearce beneficially owns 47,911 ordinary shares directly.
• Additionally, Ms. Pearce acquired 166 ordinary shares on May 29, 2026, under a Section 423 Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the primary transaction involves shares withheld for tax purposes, a standard and expected event for executives with equity compensation.

Positives

• Acquisition of 166 ordinary shares under an Employee Stock Purchase Plan indicates continued employee participation and investment in the company.
• The withholding of shares for tax obligations is a standard procedure following the vesting of equity awards, suggesting successful vesting of prior grants.

Negatives

• Disposition of 2,527 ordinary shares by a key executive, even if for tax purposes, represents a reduction in direct beneficial ownership.

Future Outlook

No specific forward-looking statements or guidance were provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for executives and directors, detailing changes in their beneficial ownership of company stock. Such transactions, particularly those related to tax withholding upon vesting of equity awards, are common and generally not indicative of a change in the executive's long-term view of the company's prospects.

Stakeholder Impact

• Shareholders: The disposition of shares by an executive, while noted, is for tax purposes and does not inherently signal a negative outlook on the company's performance. The acquisition under the ESPP shows continued employee investment.
• Employees: The acquisition under the ESPP reinforces the company's practice of offering employee stock purchase plans.
• Management: The transaction reflects standard executive compensation and tax management practices.

Key Dates

Keywords

Form 4, SEC Filing, Jazz Pharmaceuticals, JAZZ, Insider Trading, Stock Disposition, Restricted Stock Units, Employee Stock Purchase Plan, Tax Obligations, Beneficial Ownership